NCT05477862

Brief Summary

Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients. As a direct sound-based approach, CDIM does not rely on autobiographical memory and may have wider applicability and generalizability. We wish to examine if CDIM decreases anxiety in 15 cognitively healthy individuals and 15 Alzheimer Disease patients with anxiety (AD-A).

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable alzheimer-disease

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 17, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

July 28, 2022

Completed
1.2 years until next milestone

Study Start

First participant enrolled

October 15, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2026

Completed
Last Updated

March 22, 2024

Status Verified

March 1, 2024

Enrollment Period

2 years

First QC Date

July 17, 2022

Last Update Submit

March 20, 2024

Conditions

Keywords

AnxietyAlzheimerDementiaAgitationIrritabilityMusic InterventionMusic MedicineMusic Improvisation

Outcome Measures

Primary Outcomes (2)

  • Change in Neuropsychiatric Inventory (NPI) [NPI-1: pre-intervention; NPI-2: post-intervention]

    Change in NPI (NPI-2 minus NPI-1)

    Through study completion (3 years)

  • Change in Beck Anxiety Inventory [BAI-1: pre-intervention; BAI-2: post-intervention]

    Change in BAI (BAI-2 minus BAI-1)

    Through study completion (3 years)

Secondary Outcomes (5)

  • Change in Systolic Blood Pressure [SBP-1: pre-intervention; SBP-2: post-intervention]

    Through study completion (3 years)

  • Change in Heart rate [HR-1: pre-intervention; HR-2: post-intervention]

    Through study completion (3 years)

  • Change Respiratory Rate [RR-1: pre-intervention; RR-2: post-intervention]

    Through study completion (3 years)

  • Change in Skin conductance [SC-1: pre-intervention; SC-2: post-intervention]

    Through study completion (3 years)

  • Change in Resting state functional connectivity MRI

    Through study completion (3 years)

Study Arms (2)

Alzheimer Disease (AD)

EXPERIMENTAL
Behavioral: Clinically Designed Improvisatory Music

Cognitively Healthy (CH)

EXPERIMENTAL
Behavioral: Clinically Designed Improvisatory Music

Interventions

Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients.

Alzheimer Disease (AD)Cognitively Healthy (CH)

Eligibility Criteria

Age55 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Cognitively healthy individuals
  • Cognitively healthy control participants evaluated through the Northwestern Mesulam Center. BAI \> 8.

You may not qualify if:

  • Individuals with mild to moderate Alzheimer's disease
  • This group will similarly be recruited through the Mesulam Center. All individuals recruited by the research Core at the center are well characterized tests standardized across all NIH funded Alzheimer Centers across the nation. Individuals with mild to moderate neurocognitive disorder due to AD will have an MMSE greater than \>15 and Clinical Dementia Rating (CDR) between 0.5 and 2.. They will also have a history of neurocognitive-related agitation/anxiety, and a Beck Anxiety Index (BAI) greater than 8, suggestive of at least a mild level of anxiety.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mesulam Center for Cognitive Neurology and Alzheimer's Disease

Chicago, Illinois, 60611, United States

Location

Related Publications (5)

  • Bonakdarpour B, McFadden A, Zlotkowski S, Huang D, Shaker M, Shibata B, Haben W, Brashear C, Sandoval A, Breitenbach C, Rodriguez C, Viamille J, Porter M, Galic K, Schaeve M, Thatcher D, Takarabe C. Neurology Telemusic Program at the Time of the COVID-19 Pandemic: Turning Hospital Time Into Aesthetic Time During Crisis. Front Neurol. 2021 Dec 13;12:749782. doi: 10.3389/fneur.2021.749782. eCollection 2021.

    PMID: 34966344BACKGROUND
  • Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011 Sep;7(5):532-9. doi: 10.1016/j.jalz.2011.05.2410.

    PMID: 21889116BACKGROUND
  • Baird A, Samson S. Music and dementia. Prog Brain Res. 2015;217:207-35. doi: 10.1016/bs.pbr.2014.11.028. Epub 2015 Jan 31.

    PMID: 25725917BACKGROUND
  • Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol. 2002 Aug;15(4):445-50. doi: 10.1097/00019052-200208000-00007.

    PMID: 12151841BACKGROUND
  • Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, Greicius MD. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007 Feb 28;27(9):2349-56. doi: 10.1523/JNEUROSCI.5587-06.2007.

    PMID: 17329432BACKGROUND

MeSH Terms

Conditions

Alzheimer DiseaseAnxiety DisordersDementiaPsychomotor Agitation

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersDyskinesiasNeurologic ManifestationsPsychomotor DisordersNeurobehavioral ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsAberrant Motor Behavior in DementiaBehavioral SymptomsBehavior

Study Officials

  • Borna Bonakdarpour, MD, FAAN

    Northwestern Mesulam Center for Cognitive Neurology and Alzheimer Disease

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: 15 individuals with Alzheimer Disease (AD) and 15 cognitively healthy individuals.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Neurology

Study Record Dates

First Submitted

July 17, 2022

First Posted

July 28, 2022

Study Start

October 15, 2023

Primary Completion

October 15, 2025

Study Completion

January 15, 2026

Last Updated

March 22, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations